STOCK TITAN

Vaxxinity Inc - VAXX STOCK NEWS

Welcome to our dedicated news page for Vaxxinity (Ticker: VAXX), a resource for investors and traders seeking the latest updates and insights on Vaxxinity.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Vaxxinity's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Vaxxinity's position in the market.

Rhea-AI Summary
Vaxxinity, Inc. (Nasdaq: VAXX) announced its participation in three upcoming medical and investor conferences in November. The company's scientists and executives will present their findings, including the novel peptide/protein subunit COVID-19 vaccine booster UB-612, which stimulated broadly neutralizing and Fc-mediated effector antibodies in a Phase 3 clinical trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.18%
Tags
conferences
-
Rhea-AI Summary
Vaxxinity, Inc. (Nasdaq: VAXX) reported Q3 2023 financial results and a corporate update. The company made progress with clinical programs for Parkinson's and Alzheimer's diseases, and hypercholesterolemia. They also announced a potential COVID-19 booster and additions to the executive team. Financially, Vaxxinity had $42.5 million in liquid assets as of September 30, 2023, and a net loss of $13.1 million for the quarter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.46%
Tags
-
Rhea-AI Summary
Vaxxinity CEO to present at investor conferences in September.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.28%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.09%
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.5%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.1%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.44%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.31%
Tags
conferences
Vaxxinity Inc

Nasdaq:VAXX

VAXX Rankings

VAXX Stock Data

61.75M
55.31M
50.93%
12.31%
3.22%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
Merritt Island

About VAXX

vaccines against chronic diseases